Marco Martinez
Physician Assistant · Alton, TXNPI 1629700869
Payments from drug & device makers
Across 108 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$402
- AstraZeneca$351
- Viiv Healthcare Company$350
- Gilead$291
- AbbVie$240
- Abbott$211
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,872100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $402 |
| AstraZeneca | 14 | $351 |
| Viiv Healthcare Company | 10 | $350 |
| Gilead | 5 | $291 |
| AbbVie | 9 | $240 |
| Abbott | 9 | $211 |
| Amgen | 9 | $188 |
| Inspire Medical Systems, Inc. | 3 | $183 |
| Boston Scientific | 10 | $180 |
| Lilly USA, LLC | 4 | $78 |
| Boehringer Ingelheim | 3 | $78 |
| Pfizer | 3 | $77 |
| Astellas Pharma US Inc | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| GSK | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Ardelyx, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,872 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $56,752 |
| OzempicSemaglutide | 33 | $56,500 |
| RybelsusSemaglutide | 33 | $42,098 |
| LinzessLinaclotide | 48 | $27,548 |
| TrulicityDulaglutide | 14 | $22,685 |
| JardianceEmpagliflozin | 25 | $20,753 |
| Diclofenac Sodium | 39 | $864 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 14 | $729 |
| Omeprazole | 42 | $707 |
| Rosuvastatin Calcium | 28 | $675 |
| Gabapentin | 68 | $649 |
| Metoprolol Succinate | 30 | $602 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 41 | $600 |
| Ibuprofen | 134 | $552 |
| Levothyroxine Sodium | 64 | $544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $402 | $98,59866 claims |
| Lilly USA, LLCMounjaro, Trulicity | $78 | $79,43863 claims |
| AbbVieLinzess | $240 | $27,54848 claims |
| Boehringer IngelheimJardiance | $78 | $20,75325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Alton
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.